Lipoatrophy in patients with multiple sclerosis on glatiramer acetate.
Open Access
- 1 February 2004
- journal article
- case report
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences
- Vol. 31 (1) , 58-63
- https://doi.org/10.1017/s0317167100002845
Abstract
Patients with relapsing remitting multiple sclerosis on the disease modifying therapy of glatiramer acetate may be experiencing an adverse reaction of lipoatrophy at the sites of their subcutaneous injections. The purpose of this study was to complete a full examination of the injection site areas for users of glatiramer acetate, and to examine the relationship between lipoatrophy and patient characteristics.Keywords
This publication has 7 references indexed in Scilit:
- Longitudinal Assessment of Health-Related Quality of Life (HRQL) of Patients with Multiple SclerosisInternational Journal of MS Care, 2000
- Alternative Medicine and Multiple Sclerosis: An Objective Review from an American PerspectiveInternational Journal of MS Care, 2000
- Localized lipoatrophy after prolonged treatment with copolymer 1.Zeitschrift für Neurologie, 2000
- Localized Lipoatrophy After Glatiramer Acetate Injection in Patients With Remitting-Relapsing Multiple SclerosisArchives of Dermatology, 1999
- Measurement of Health-Related Quality of Life in Multiple Sclerosis PatientsCanadian Journal of Neurological Sciences, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Copolymer 1Neurology, 1995